Cardiovascular disease: risk assessment and reduction, including lipid modification
KEYWORDS: people, cvd, risk, treatment, statin, statins, committee, recommendations, prevention, evidence, cholesterol, recommendation, lipid-lowering, primary, amended

healthcare professionals about lifetime risk calculators. It is not clear if use of lifetime risk tools will result in longer consultations. The committee agreed that the online calculators for lifetime risk tools such as QRISK- lifetime were easy to complete and provided some interpretation of the risk scores to aid discussions, but acknowledged that lifetime risk assessment would not be done for everyone. The committee believe that using lifetime risk tools may have a long-term benefit in encouraging people to participate in lifestyle changes or engage in treatment, if appropriate. Given this, any additional time costs were considered likely to improve management of CVD risk and reduce future CVD events. Return to recommendation Aspirin for primary prevention of cardiovascular disease Recommendation 1.2.1 Why NICE made the recommendation NICE's surveillance team reviewed the evidence about aspirin for the primary prevention of CVD. Based on the review, NICE decided to add a do not routinely offer recommendation about this. For full details see the January 2023 exceptional surveillance report. Return to recommendation Cardioprotective diet Recommendation 1.3.2 Why the committee made the recommendation There was no available evidence comparing the effectiveness of dietary cholesterol strategies with normal diets for adults with and without
